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Gregory L. Moneta, MD, Section EditorAssociation Between Surgical Care Improvement Program Venous
Thromboembolism Measures and Postoperative Events
Altom LK, Deierhoi RJ, Grams J, et al. Am J Surg 2012;204:591-7.
Conclusion: There is no association between rates of venous throm-
boembolism (VTE) and adherence to the Surgical Care Improvement
Program (SCIP) implemented measures to reduce VTE.
Summary: SCIP was implemented by the Centers for Medicare and
Medicaid Services (CMS) in 2006. The goal of SCIP is to reduce surgical
complications, surgical site infections, adverse cardiac events, and thrombo-
embolism by 25%. SCIP is a core measure collected by the Joint Commis-
sion. In-hospital adherence to SCIP measures is reported publicly. Deep
venous thrombosis and pulmonary embolism are known to be potentially
signiﬁcant causes of postoperative morbidity and mortality. SCIP intro-
duced two VTE prophylactic measures for surgical procedures as reﬂected
in guidelines from the American College of Chest Physicians. SCIP-VTE-
1 measures whether VTE prophylaxis was ordered, and SCIP-VTE-2
measures whether prophylaxis was received; both #24 hours of surgery.
This study sought to determine the rates of adherence to SCIP-VTE guide-
lines, to identify factors for nonadherence, and to analyze relationships
between SCIP guideline adherence and VTE events in the context of other
patient and procedure factors. This was a retrospective cohort study of data
from the VA Surgical Quality Improvement Program from 2006 to 2009.
There were 30,531 surgeries analyzed. Patient demographics, comorbid-
ities, and surgical characteristics associated with VTE were summarized.
VTE rates were compared by SCIP-VTE adherence. VTE was modeled
by adherence to SCIP and adjusting for multiple associated factors using
multivariable logistic regression. Of the 30,531 surgeries evaluated, 89.9%
adhered to SCIP-VTE, and 1.4% experienced VTE. Obesity, smoking, func-
tional status, weight loss, emergency status, age >64 years, and surgical time
were identiﬁed by logistic regression to be associated with VTE. SCIP-VTE
adherence was not associated with VTE (1.4% vs 1.33%; P ¼ .3). The lack of
association of SCIP-VTE with VTE remained even after adjustment for
compounding variables.
Comment: Most prior analyses of SCIP measures have focused on
surgical site infection. These analyses have not provided convincing evidence
that adherence to SCIP surgical site infection measures reduces the rate of
surgical site infections. Similarly, this study suggests compliance with SCIP-
VTE prevention measures has no measurable association with events that
are intended to be prevented by adherence to the SCIP-VTE measures.
SCIP-VTE measures may be ineffective or too limited to compensate for
the large variation and complexity of patient and surgical factors contrib-
uting to VTE. No one will argue that reduction of surgical associated
VTE is a desirable goal. However, the SCIP regulations should be consid-
ered for elimination or modiﬁcation if they are not found to produce their
intended results.Renal Sympathetic Denervation for Treatment of Drug-Resistant
Hypertension: One-Year Results From the Symplicity HTN-2
Randomized Controlled Trial
Esler MD, Krum H, Schlaich M, and the Symplicity HTN-2 Investigators.
Circulation 2012;126:2976-82.
Conclusion: Renal denervation provides safe and sustained reduction
of blood pressure to 1 year.
Summary: The number of adults with hypertension is expected to
grow to >1.5 billion worldwide by 2025 (Kearney PM et al, Lancet
2005;365:217-23). There is a subset of patients with particularly difﬁcult
to control hypertension who, despite adherence to three or more drugs,
continue to have uncontrolled or resistant hypertension (Mahfoud F et al,
Deutsches Arzteblatt Internation 2011;108:725-31). Resistant hyperten-
sion prevalence in the United States ranges from 13% to 30% (Persell SD
et al, Hypertension 2011;57:1076-80). There is activation of the renal
sympathetic system in patients with essential hypertension. Efferent sympa-
thetic outﬂow to the kidneys results in elevation of blood pressure via release
of renin. In addition, afferent nerve signaling from the kidneys with renal
injury also stimulates sympathetic outﬂow from the central nervous system.
There have been preclinical studies of renal denervation in animal models of
hypertension that provide direct evidence of blood pressure loweringthrough renal denervation. This suggests a signiﬁcant role of the sympa-
thetic nervous system of the kidney in the pathogenesis of hypertension
(DiBona GF et al, Physiol Rev 1997;77:75-197). Renal denervation can
be accomplished with the application of radiofrequency energy in short
bursts along the length of the main renal arteries. The result is ablation of
renal nerves that lay within and just beyond the adventitial tissue of the renal
arteries. The Symplicity HTN-1 Trial, along with a registry of patients with
resistant hypertension treated by renal denervation, have demonstrated
reductions in ofﬁce-based blood pressure, apparently without serious
adverse events (Investigators Symplicity HTN-1, Hypertension
2011;57:911-7). Symplicity HTN-2 is a multicenter randomized trial that
previously demonstrated catheter-based renal denervation provided signiﬁ-
cant lowering of blood pressure in treatment-resistant patients at 6 months
after the procedure compared with control, medication-only patients. In this
report, the authors present longer follow-up and include 6-month crossover
results of Symplicity HTN-2. Eligible patients were taking three or more
antihypertensive medicines and had a baseline systolic blood pressure
$160 mm Hg ($150 mm Hg for type 2 diabetic patients). After the
6-month end points were met, renal denervation was permitted in control
patients. Here the authors present 1-year results of 47 patients randomized
to immediate renal denervation and 6-month postprocedure results for
crossover patients. At 12 months after the procedure, the mean fall in ofﬁce
systolic blood pressure in the initial renal denervation group (28.1 mm
Hg; 95% conﬁdence interval, 35.4 to 20.7; P < .001) was similar to the
6-month fall (31.7 mm Hg; 95% conﬁdence interval, 38 to 25.0;
P ¼ .16 compared to the fall at 6 months). The mean systolic blood pressure
of the crossover group 6 months after the procedure was signiﬁcantly lower,
from 190 6 19.6 to 166.3 6 24.7 mm Hg (change, 23.7 6 27.5;
P < .001). There was one renal artery dissection associated with guide cath-
eter insertion in the crossover group and one hypotensive episode that
resolved with medication adjustment.
Comment: The mechanisms of essential hypertension are slowly
being unraveled. It appears renal sympathetic nerve activation has a role
in the production of essential hypertension and that denervation of the
kidney, with catheter based techniques, has the potential to interrupt renal
afferent and efferent nerves, resulting in decreased sympathetic outﬂow to
the kidneys, reduced renin release, decreased sodium retention, increased
renal blood ﬂow, and lower blood pressure. Thus far, there has not been
animal or clinical evidence that use of the Simplicity catheter to denervate
the kidneys results in sustained damage to the renal arteries. There has
also been no documentation of adverse effects on renal function at 6 and
12 months after renal denervation. Renal denervation appears to have the
potential to provide safe and effective adjunctive treatment for drug-resis-
tant hypertensive patients.Usefulness of Aspiration of Pulmonary Emboli and Prolonged Local
Thrombolysis to Treat Pulmonary Embolism
Cuculi F, Kobza R, Bergner M, et al. Am J Cardiol 2012;110:1841-5.
Conclusion: In patients with pulmonary embolism (PE), manual aspi-
ration and application of prolonged thrombolysis is feasible and safe, with
signiﬁcant improvement in pulmonary artery pressures.
Summary: A catheter-based intervention for signiﬁcant PE can be an
alternative to systemic thrombolysis or surgical embolectomy. There are
multiple catheter-based techniques that can be used in the treatment of
PE, including thrombus fragmentation, rheolytic thrombectomy, suction
thrombectomy, and rotational thrombectomy. In this report, the authors
describe a new pharmacomechanical approach to catheter-based treatment
of PE using prolonged infusion of urokinase directly into the pulmonary
arteries. Manual aspiration of thrombus using guide catheters was followed
by introduction of thrombolysis catheters and a local bolus of urokinase.
Lysis catheters were left in place and repeat pulmonary artery angiography
and right-side cardiac catheterization performed 3 days later. Sixty-three
patients with a mean age of 60 6 15 years were treated over 8 years. The
PE was massive in 17 patients (27%) and submassive in 46 (73%). Mean
pulmonary artery (PA) pressure was 35 6 10 mm Hg, and 54% had central
bilateral PE. Five patients died, one before, one during, and three after
intervention. Nine patients (14%) had major bleeding episodes. Bleeding
was not responsible for any fatal outcome. After 3.3 6 1.0 days, 49 of 581171
